Genprex, Inc. (GNPX) intrinsic value & 10-year financials
Genprex, Inc. (GNPX) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $2.11
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -225.9%
- Free cash flow (FY2025)
- —
GNPX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$16.2M | — | — | — | -323.8% |
| FY2024 | $0 | -$21.1M | — | — | — | -468.6% |
| FY2023 | $0 | -$30.9M | — | — | — | -209.3% |
| FY2022 | $0 | -$23.7M | — | -$17.8M | — | -75.0% |
| FY2021 | $0 | -$19.6M | — | -$14.3M | — | -54.3% |
| FY2020 | $0 | -$17.9M | — | -$14.0M | — | -105.7% |
| FY2019 | — | -$10.7M | — | -$7.0M | — | -179.0% |
| FY2018 | $0 | -$12.4M | — | -$6.9M | — | -265.8% |
| FY2017 | $0 | -$3.3M | — | -$2.2M | — | -322.8% |
| FY2016 | $0 | -$4.1M | — | -$1.3M | — | -254.3% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Genprex, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Genprex, Inc. has historically struggled to out-earn its cost of capital, averaging just -25.5% ROIC.
Genprex, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Genprex, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.